An article on the Statnews website reports about some apparent success treating COVID-19 patients with the Gilead Sciences’ drug remdesivir in a clinical trial at a Chicago hospital.
From the article:
‘The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.
‘“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.’
The full article can be read here:
This report has apparently contributed to steep gains in stock market futures in the U.S. financials markets ahead of Friday’s market opening.